UNSPSC 51171615: Calcium polycarbophil or polycarbophil calcium

This classification denotes a synthetic polymer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W25LM17A4W. European Medicines Agency schedules Polycarbophil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03927MIG.

Polycarbophil generally arises in the molecular formula (C6H10O2)N.(C3H4O2)N. The term POLYCARBOPHIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) POLYCARBOPHIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, CALCIUM POLYCARBOPHIL remains the US FDA Preferred Term for this commodity. Calcium polycarbophil bears US NLM identifiers UMLS ID C0054480 and NCI Concept Code C28902. SMILES: NONE.

UNSPSC 51171615 Calcium polycarbophil or polycarbophil calcium is a Commodity code that nominally describes a single active pharmaceutical ingredient used as a bulk laxative agent, but recent state and local procurement activity shows no direct solicitations for this specific ingredient. The three recent opportunities tagged to this code—offender drug testing services, a therapeutic pharmacy initiative request for information, and a multistate generic pharmaceutical cooperative purchasing agreement—represent misalignments between the code assignment and the actual scope of work. The drug testing RFP from Collin County covers specimen collection and laboratory screening and confirmation services with no pharmaceutical supply component. The Texas HHS RFI addresses direct-to-manufacturer prescription fulfillment strategies for a state pharmacy benefit program. The MMCAP cooperative purchasing RFP solicits generic multi-source pharmaceuticals and OTC products broadly, without identifying calcium polycarbophil as a line item or focus area. None of these opportunities reflect procurement of calcium polycarbophil or its equivalent formulation as a finished pharmaceutical product or raw ingredient.

The code shows little relevant recent activity aligned with its nominal scope. State and local procurement of bulk pharmaceutical actives such as calcium polycarbophil would typically emerge through institutional pharmacy purchasing, cooperative drug purchasing vehicles, or direct manufacturer agreements with state Medicaid agencies, correctional health systems, or public health departments. The current record provides no evidence of such procurement under this code. Business development professionals evaluating this code should note the mismatch between the UNSPSC assignment and posted opportunities, and monitor for future RFPs explicitly naming calcium polycarbophil or bulk laxative products from issuing bodies such as state Medicaid programs, state correctional health agencies, or multistate pharmacy cooperatives.